Coherus Biosciences Inc. (CHRS) stock prices were down by 3.61% as of the market closing on August 18th, 2021. This brought the price per share down to USD$14.14 at the end of the trading day. Subsequent premarket fluctuations have seen the stock surge by 19.66%, bringing it up to USD$16.92.
CHRS-01 Stock’s CHOICE-01 Trial
August 18th, 2021 saw CHRS stock announce positive interim results from the pivotal study CHOICE-01. The announcement was made in collaboration with Junshi Biosciences. The randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab. The treatment was administered with chemotherapy as a first-line treatment of advanced squamous or non-squamou non-small cell lung cancer (NSCLC). The interim analysis met the primary endpoint, which demonstrated a statistically significant and clinically meaningful improvement in progression-free surivive. PFS was measure per RECIST v1.1, as compared to chemotherapy alone.
Upcoming Presentation
The results of the study will be summarized on September 13th in an oral presentation by Professor Jie Wang, MD, Ph.D. The exhibition will take place during the Mini Oral Session at the 2021 World Conference on Lung Cancer (WCLC). The event is hosted by the International Association for the Study of Lung Cancer (IASLC), with the abstract being available on the WCLC website.
About the Study
Patients enrolled in the CHOICE-01 study exhibited advanced non-small cell lung cancer. The patients demonstrated the clinical benefit of toripalimab in another first-line setting. This builds on the evidence of efficacy in first-line studies in nasopharyngeal carcinoma and esophageal squamous cell carcinoma. The clinical profile of the treatment has been established as excellent across various tumor types. The company is setting the stage to pursue registration for toripalimab for a range of indications in China, the U.S. and other markets.
CHRS Stock’s Resounding Success
The efficacy and safety data from the study were compelling, demonstrating the treatment’s potential to deliver the significant benefits. The PD-1 class of checkpoint inhibitor drugs has been consolidated in the treatment of patients with non-small cell lung cancer. As data is gathered over the course of the pivotal studies, the treatment is showing itself to be an excellent checkpoint inhibitor. The company is anticipating results from additional oncological Phase 3 studies.
Future Outlook for CHRS Stock
The company reported highly promising developments in its CHOICE-01 study, with CHRS stock excited to further progress their flagship treatment. The company is keen to accelerate the commercialization and proliferation of their treatment. Investors are hopeful for significant and sustained increases in shareholder value.
